PeptiCore is focusing on development of break-through innovations of anti-bacterial drugs.
Our first product, PheLizTM, is a first in class antibiotic, active against a wide range of bacterial and fungal species, with a unique structure making it efficacious on antibiotic-resistant microbial strains and exhibiting an unprecedented resilience to microbial resistance.
Antimicrobial resistance (AMR) is a global health and development threat.
WHO has declared that AMR is one of the top 10 global public health threats facing humanity.
In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result.
The global Antibiotic Resistance market is valued at US$ 10.82 Billion in 2021, and it is expected to reach US$ 18.34 Billion by 2030, with a CAGR of 6.1% during the forecast period of 2022-2030.
PheLizTM has a unique structure of combinatorial peptide cocktail that contains up multiple peptide chains, making it efficacious on antibiotic-resistant microbial strains and exhibiting an unprecedented resilience to microbial resistance.
Attacking the bacteria by combinatorial different sequences of random antimicrobial peptides makes it unable to develop resistance to all of the sequences in a reasonable time before the total extinction of their population.